Company intelligence / Profile preview

Sinohealth

Shanghai, Shanghai, Chinair.sinohealth.cn ↗

Ownership: Private
Development stage: Other

Overview

Sino Health was a healthcare investment holding platform with a portfolio including three commercial stage products and at least one pipeline product under New Drug Application review. The company was acquired by Nuance Pharma in January 2022 to strengthen Nuance's presence in emergency care and expand its commercial capabilities. No detailed clinical results are publicly available.

Therapeutic areas: OtherPulmonologyNeurologyWomen's Health
Modalities: Small moleculeBiologic
Industry: Biotech

Beyond the preview

Go deeper on Sinohealth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinohealth.

Explore the full profile